i
Multidrug-resistant tuberculosis : tools for tackling a new face of an old foe
-
March 18, 2014
Details:
-
Alternative Title:Public health importance of drug-resistant tuberculosis;Rapid diagnosis of MDR TB: a laboratory systems-based approach;Rational use of new drugs for treatment of MDR TB: context and challenges;Drug resistance in TB: what public health can do now and in the future;
-
Journal Article:Public health grand rounds
-
Personal Author:
-
Corporate Authors:
-
Description:PDF file of the speakers' PowerPoint presentations at CDC Public health grand rounds: Tuesday, March 18, 2014 at 1 p.m. - 2 p.m.
Tuberculosis is an ancient disease that remains an important global cause of morbidity and mortality. In most cases, TB can be treated and cured by taking a combination of several drugs for 6 to 12 months. When inappropriate or incomplete treatment takes place, however, TB bacteria can develop resistance to multiple drugs. Treatment of drug-resistant TB is currently longer, more toxic, more complex, and less effective than for drug-susceptible TB. In 2011, less than 10% of the total estimated multidrug-resistant TB (MDR TB) cases were detected and annually, there are approximately 500,000 cases of MDR TB, and 150,000 deaths. Although there are simple rapid tests that have improved the diagnosis of the disease, there is immense potential to increase the number of persons diagnosed with MDR TB, and diagnose them more quickly so that they can begin treatment sooner.
Presented by: Sarita Shah, MD, MPH Associate Chief for Science, International Research and Programs Branch, Division of TB Elimination, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC [“The Public Health Importance of Drug-resistant Tuberculosis”]; Tom Shinnick, PhD Associate Director for Global Laboratory Activities, Division of TB Elimination National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC [“Rapid Diagnosis of MDR TB: A Laboratory Systems-based Approach”]; Christian Lienhardt, MD, DTM, MSc, PhD Senior Research Advisor, Stop TB Department, World Health Organization, Geneva, Switzerland [“Rational Use of New Drugs for Treatment of MDR TB: Context and Challenges”]; Tom Kenyon, MD, MPH Director, Center for Global Health, CDC [“Drug Resistance in TB: What Public Health Can Do Now and in the Future”].
Facilitated by: John Iskander, MD, MPH, Deputy Scientific Director, Public Health Grand Rounds, Susan Laird, MSN, RN, Communications Manager, Public Health Grand Rounds.
-
Subjects:
-
Document Type:
-
Genre:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
Supporting Files
-
No Additional Files
More +